A Rare Case of Life-Threatening Extensive Mucocutaneous Adverse Reaction Induced by Docetaxel in a Breast Cancer Patient: Toxic Epidermal Necrolysis, a Case Report with Review of Literature

Shiv Prasad Shrivastava1 Aditya Elhence1 Prutha Jinwala1 Shashank Bansal1 Prakash Chitalkar1 Shweta Bhatnagar2 Rajesh Patidar1 Vikas Asati1

1Department of Medical Oncology, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh, India
2Department of Radiology, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh, India


Abstract
Fever and extensive necrosis with 30% or more epidermal involvement along with mucous membrane is known as toxic epidermal necrolysis (TEN). It is a life-threatening mucocutaneous disease and is usually drug induced. We report a rare case of docetaxel-induced TEN. A patient with metastatic breast carcinoma received single agent docetaxel and developed severe skin and mucous membrane reaction involving more than 30% of the skin, and managed conservatively in intensive care unit but she succumbed to her illness. Although common toxicities reported with docetaxel include alopecia, nail damage, myelosuppression, and erythema multiforme major, TEN after docetaxel is very rare and can be a life-threatening complication as in our case.

Keywords
►docetaxel
►toxic epidermal necrolysis
►breast cancer
►case report

Introduction
Docetaxel is derived from the needles Taxus baccata (European yew tree). It binds to microtubules and enhances tubulin polymerization leads to inhibition of mitosis and cell division. Reported cutaneous toxicities include alopecia, hypersensitivity with skin rash, pigmentation, onycholysis, palmar–plantar erythrodysesthesia, cutaneous lupus, and erythema multiforme. In our case, patient developed toxic epidermal necrosis (TEN) following administration of docetaxel, which is a rare side effect of docetaxel.

Case Report
A 39-year-old woman was diagnosed with metastatic breast cancer (liver and lung metastasis). She was on palliative chemotherapy docetaxel 75 mg/m² with trastuzumab (8 mg/kg in first cycle followed by 6 mg/kg in consecutive cycles) on a 3-weekly schedule. She tolerated two cycles of planned therapy. Nine days after third cycle of docetaxel and trastuzumab on August, 08, 2021, she presented with complaints of blisters that later ruptured with excoriation of skin over both hands, feet and back, oral mucositis with difficulty in swallowing, sticky eyelids with conjunctival redness,
multiple episodes of vomiting, loose motions, shortness of breath, and low-grade intermittent fever.

On examination, her Eastern Cooperative Oncology Group performance status was 4, pulse rate 125/min, feeble, rhythmic, normovolumic, hypotension (90/60 mm Hg), tachypnea (respiratory rate >21/min), afibrile, saturation of peripheral oxygen 80%, and Grade III oral mucositis. Dermatological examination showed extensive erythematous desquamation with ruptured blisters involving skin of hands, lips, feet, vulva, perianal region, and lower back involving more than 30% of body surface was noted with mucosal involvement (Fig. 1). Crepitations was present in both lower zones of lung. Patient was admitted in intensive care unit. Laboratory evaluation showed hemoglobin of 9.4 g/dL (11–14), total leukocyte count 32.27 × 10⁹/L (4–10 × 10⁹) with 82% neutrophils, 11% lymphocytes, 7% monocytes, and platelets of 2.84 lakh/mm³, creatinine 1.1 mg/dL (0.5–1.5 mg/dL), and blood urea 102 mg/dL (15–40 mg/dL). Bilirubin of 4.11 mg/dL (0.5–1.5 mg/dL), serum glutamic oxaloacetic transaminase 54 U/L (0–40 U/L) and serum glutamic-pyruvic transaminase 40 U/L (0–45 U/L), random blood sugar 164 mg/dL, pH 7.20 (7.35–7.45), bicarbonate 16 mEq/L (22–26 mEq/L) and rest other investigations were within normal limits. Chest X-ray showed dense homogenous opacity in left hemithorax obscuring left costophrenic angle suggestive of left-sided pleural effusion.

Punch biopsy taken from the lesions on the left forearm and left medial foot, on hematoxylin-eosin-stained specimen, light microscopy features suggested TEN (Fig. 2). Diagnosis of docetaxel-induced TEN was confirmed and managed with intravenous fluids, vasopressors, steroids, antibiotics, and total parenteral nutrition with hypothermia prevention. Secondary infection control and skin care were instituted. Unfortunately, patient died on the sixth day of hospitalization.

**Discussion**

Docetaxel a microtubule inhibitor got first approved in 1996 for the treatment of metastatic breast cancer patients who relapsed after anthracycline-based chemotherapy.¹,²

Side effects of docetaxel include neutropenia, anemia, thrombocytopenia, and minor rash to severe anaphylaxis reactions, which are reversible on stopping treatment. In literature, various skin reactions reported includes maculo-papular drug rash, alopecia, nail hyperpigmentation and destruction, onycholysis, palmar–plantar erythrodysesthesia, cutaneous lupus and scleroderma, photolichenoid eruption, erythema multiforme major, and persistent serpentine supravenous hyperpigmented eruption.⁶

Only a few cases of life-threatening TEN-like adverse reaction due to docetaxel have been reported till date. As per Gell and Coombs system, docetaxel causes delayed onset T-cell-mediated type IVc hypersensitivity reaction, and can occur days to weeks after exposure.

Immunophenotype study of lymphocytes in blister fluid of TEN lesions suggested a cell-mediated cytotoxic reaction against keratinocytes leading to apoptosis. Further studies showed that cytotoxic T cells are drug specific, human leukocyte antigen (HLA) class I restricted, and directed against the native form of the drug rather than against a reactive metabolite. Drugs directly bind to major histocompatibility complex class I and the T cell receptor leading to stimulation the immune system, clonal expansion of drug-specific cytotoxic T cells

---

**Fig. 1** (a) Photograph of erythematous bullous eruptions over feet. (b) Photograph of hand with skin excoriation with erythema after rupture bullous lesion. (c) Both eyelid skin excoriation. (d) Conjunctival hemorrhage. (e) Mucosal lesion of lips and tongue.
cells, killing of keratinocytes via release of soluble death mediators, including granulysin.12

Drugs directly bind to the HLA class I peptide pouch,13 and change the repertoire of peptides recognized as foreign14 and make the HLA–drug complex recognized as foreign.

Medications are most common cause for TEN. TEN involves sloughing of more than 30% of the body surface area. It starts with malaise, fever, and involvement of mucous membranes in nearly all cases.15 Toxic epidermal necrosis is distinguished from Stevens–Johnson’s syndrome (SJS) by severity and percentage of involvement of body surface area.

The skin lesions, that is, erythematous macules, patches, and almost 50% of cases start with erythema lead to full-thickness epidermal necrosis and skin resembles that of extensive thermal injury as seen in our patient. TEN is a potential life-threatening adverse reaction with risk for complications such as secondary infections, dehydration, renal, gastrointestinal involvement, and finally scarring with cosmetic and functional problems.

Anticancer medications reported to cause severe cutaneous adverse reactions (SJS and TEN), alkylating agents (treosulfan, chlorambucil, temozolomide, procarbazine), plant alkaloids (paclitaxel, docetaxel, etoposide), anthracyclines (doxorubicin), antimetabolites (methotrexate, cytarabine, fludarabine, gemcitabine), antitumor antibiotics (bleomycin), epidermal growth factor receptor inhibitor (afatinib, cetuximab, panitumumab), immune checkpoint inhibitors (nivolumab, pembrolizumab), etc.

Prevention of adverse effects can be with premedication, which can be started from a day before infusion up to 5 days. Once TEN is established, management involves multispecialty supportive care with critical care, skin specialist, plastic surgery, nutrition specialist and infectious disease physicians involved in fluid and electrolyte management, wound care, nutritional support, and treatment of superinfection. Data regarding use of corticosteroids are mixed, as their use may increase risk of sepsis in TEN.16

The Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) prognostic scoring system which is used to rapidly evaluate individual patient on admission. Overall mortality rates of 25 to 35% have been seen with TEN using SCORTEN prognostic scoring system which is used to determine prognosis on days 1 and 3 of hospitalization.17

Mortality rate (%) as follows:
• 0 to 1 = 3.2% (confidence interval [CI]: 0.1–16.7)
• 2 = 12.1% (CI: 5.4–22.5)
• 3 = 35.3% (CI: 19.8–53.5)
• 4 = 58.3% (CI: 36.6–77.9)
• ≥ 5 = > 90% (CI: 55.5–99.8)

The SCORTEN score in our case was 5, which suggests > 90% risk of mortality. The occurrence of TEN after third cycle of docetaxel-based therapy in our case should caution us toward the rarity and unpredictability of this toxic reaction (►Table 1).

Table 1 Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN)

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Score</th>
<th>Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 40 y</td>
<td>0</td>
<td>39 y</td>
</tr>
<tr>
<td>≥ 40 y</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Associated cancer</td>
<td>No</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 120</td>
<td>0</td>
<td>125 beats/min</td>
</tr>
<tr>
<td>&gt; 120</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Detached or compromised body surface area</td>
<td></td>
<td>&gt;30% of body surface area</td>
</tr>
<tr>
<td>&lt; 10%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>≥ 10%</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Serum blood urea nitrogen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 28 mg/dL (10 mmol/L)</td>
<td>0</td>
<td>102 mg/dL</td>
</tr>
<tr>
<td>&gt; 28 mg/dL (10 mmol/L)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Serum bicarbonate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 20 mEq/dL (≥ 20 mmol/L)</td>
<td>0</td>
<td>16 mEq/dL</td>
</tr>
<tr>
<td>&lt; 20 mEq/dL (&lt; 20 mmol/L)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Serum glucose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 250 mg/dL (≤ 13.88 mmol/L)</td>
<td>0</td>
<td>164 mg/dL</td>
</tr>
<tr>
<td>&gt; 250 mg/dL (&gt; 13.88 mmol/L)</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

SCORTEN score 5
Conclusion

Docetaxel-induced TEN is a rare but fatal complication. Early recognition and intensive management with supportive care by team of specialist can limit this life-threatening complication of a commonly used cytotoxic drug in cancer management.

Ethics

The authors certify that they have obtained an Ethics committee approval for publication (ECR/748/Inst/MP2015-EE/18, dated: 22 October 2021) from the institutional ethics committee of Sri Aurobindo Institute of Medical Sciences.

Funding

None.

Conflict of Interest

None declared.

References